Topiramate
Tirzepatide, semaglutide more efficacious than other FDA-approved drugs for weight loss
Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.
Less than 1% of Military Health System beneficiaries use an obesity medication
Obesity medications were prescribed to very few Military Health System beneficiaries between October 2017 and September 2022, according to a study published in Obesity.
Childhood autism may be linked to prenatal exposure to antiseizure medication
Autism spectrum disorder incidence was higher for children with prenatal exposure to antiseizure medications vs. the general population, but some associations weakened after adjusting for treatment indication, researchers reported.
Most adults with obesity are not prescribed obesity medication
Most adults with obesity were not prescribed an obesity medication from 2015 to 2023, and of those prescribed an agent, 55% had at least one prescription fill, according to study data published in Diabetes, Obesity and Metabolism.
Most adults prescribed obesity drugs discontinue use at 3 months
More than 80% of adults who are prescribed an obesity medication discontinue taking them at 1 year, though persistence rates are higher for adults receiving semaglutide and liraglutide, according to study data.
Weight loss with anti-obesity medications comparable for older, younger adults
DALLAS — Older adults who received anti-obesity medications lost a similar amount of weight at 3 to 5 years as younger adults, with no increased side effects, according to research presented at ObesityWeek.
Top-dose phentermine/topiramate cost-effective after 5 years for adolescents with obesity
Top-dose phentermine/topiramate as an adjunct to lifestyle counseling is the most cost-effective strategy for treating adolescents with obesity over 5 years, according to findings from an economic microsimulation model.
FDA drug safety program mitigates prenatal exposure to phentermine-topiramate
Prenatal exposure to topiramate — which has been linked to birth defects — was lower among those using it in combination with phentermine than those taking topiramate alone, data show.
FDA approves phentermine/topiramate for pediatric chronic weight management
The FDA approved a supplemental indication for phentermine/topiramate extended-release capsules for chronic weight management in pediatric patients aged 12 years and older with obesity, according to a press release.
CV implications of newer obesity medications
Obesity, recognized as a chronic medical condition, affects more than 30% of adults in the United States and directly contributes to increased risk for CVD.